Introduction {#Sec1}
============

Patients with diabetes mellitus are at increased risk for cardiovascular disease (CVD), which is the leading cause of diabetes-related morbidity and mortality \[[@CR1]\]. Previous studies have reported that low serum bilirubin concentration is associated with an increased risk of CVD \[[@CR2], [@CR3]\]. Conversely, higher serum bilirubin concentrations were associated with a decreased risk of CVD in a prospective study of serum bilirubin and CVD in the Framingham Offspring Study \[[@CR4]\]. However, the relationship of serum bilirubin concentration to left ventricular geometry in patients with type 2 diabetes mellitus (T2DM) has not been extensively explored. Thus, this study was designed to determine that relationship in patients with T2DM without overt cardiovascular disease.

Methods {#Sec2}
=======

The methods used in this paper are similar to those used in a previously published article \[[@CR5]\].

Subjects {#Sec3}
--------

The study enrolled 158 Japanese patients (91 men, 67 women) with T2DM who had been admitted to the metabolic ward of Tagawa Municipal Hospital for glycemic control from October 2013 to March 2017. The diagnosis of T2DM was confirmed according to the criteria of the American Diabetes Association/World Health Organization or by a medical history of diabetes. The study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of our hospital. Written informed consent was obtained from each patient. Patients with overt heart failure, New York Heart Association Functional Classification greater than I, left ventricular ejection fraction (LVEF) less than 50%, history of coronary artery disease, severe valvulopathy, chronic atrial fibrillation, or creatinine clearance less than 30 ml/min, and those receiving insulin treatment, were excluded.

All patients underwent clinical evaluation, laboratory assessment, and echocardiographic examination. Body mass index was calculated as weight in kilograms divided by height in meters squared. Concentrations of serum bilirubin, fasting plasma glucose, hemoglobin A1c (HbA1c), immunoreactive insulin, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), uric acid, creatinine, and urinary albumin, as well as creatinine clearance, were measured. Initially, HbA1c levels were determined using the criteria of the Japanese Diabetes Society. These concentrations were converted to National Glycohemoglobin Standardization Program concentrations by adding 0.4% to the Japanese Diabetes Society concentrations \[[@CR6]\].

Echocardiography {#Sec4}
----------------

All echocardiographic examinations were performed with the Vivid E9 cardiovascular ultrasound machine (GE Healthcare, Chicago, IL, USA). The overall single-dimensional left ventricular measurements and the two-dimensional views were obtained according to the recommendations of the American Society of Echocardiography \[[@CR7]\]. We used the Devereux modified cube formula to calculate left ventricular mass (LVM) \[[@CR8]\]. To account for gender and body size variations, left ventricular mass was indexed to height^2.7^, with a boundary of 51 g/m^2.7^ to define left ventricular hypertrophy in both genders \[[@CR9]\]. Relative wall thickness (RWT) was calculated as twice the posterior wall thickness (PW) divided by the left ventricle diastolic diameter. It was considered increased when greater than 0.42 \[[@CR10]\]. RWT and left ventricular mass index (LVMI) were used to characterize left ventricular geometry as normal (i.e., normal LVMI and normal RWT), concentric remodeling (normal LVMI and increased RWT), concentric hypertrophy (increased LVMI and increased RWT), and eccentric hypertrophy (increased LVMI and normal RWT). All measurements were made by experienced physicians who were blinded to patients' clinical data and outcomes.

Statistical Analysis {#Sec5}
--------------------

All statistical analyses were performed using JMP statistical software, Version 13 (SAS Institute Inc., Cary, NC, USA). For univariate analysis of the relationship of each parameter with serum bilirubin concentration, RWT and LVMI, continuous variables were analyzed using Spearman's rank correlation and categorical variables using the Mann--Whitney *U* test. Variables significant in the univariate model were entered into a multivariate linear regression analysis. Continuous variables that were not normally distributed according to the Kolmogorov--Smirnov test were logarithmically transformed. Categorical variables of left ventricular geometry were analyzed via the Chi square test, using Fisher's exact test. Continuous variables were presented as median and interquartile range (IQR) and categorical variables as absolute number (%). A *P* value less than 0.05 was considered statistically significant.

Results {#Sec6}
=======

The clinical, anthropometric, and metabolic characteristics of the study groups are shown in Table [1](#Tab1){ref-type="table"}. The study cohort consisted of 91 men and 67 women, with median age 63 years (IQR 54--69 years), median body mass index 25.0 kg/m^2^ (IQR 22.1--28.4 kg/m^2^), and median duration of diabetes 8 years (IQR 2--14 years). Median systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 130 (IQR 120--144) and 78 mmHg (IQR 70--87 mmHg), respectively. Fasting plasma glucose and HbA1c were 160 mg/dl (IQR 126--217 mg/dl) and 9.5% (IQR 8.4--11.5%). Serum bilirubin concentration and urinary albumin were 0.8 mg/dl (IQR 0.6--0.9 mg/dl) and 12.6 mg/day (IQR 6.8--44.4 mg/day). Echocardiographic data showed that interventricular septum thickness (IVS), PW, LVMI, RWT, and LVEF were 9 mm (IQR 8--10 mm), 9 mm (IQR 8--10 mm), 80 g/m^2.7^ (IQR 71--92 g/m^2.7^), 0.39 (IQR 0.36--0.41), and 67% (IQR 64--71%), respectively. With respect to diabetes treatment, 42.4% of enrolled patients were treated with sulfonylurea, 1.9% were treated with glinide, 28.5% were treated with biguanide, 10.1% were treated with thiazolidinedione, 16.5% were treated with α-glucosidase inhibitor, 51.9% were treated with dipeptidyl peptidase-4 inhibitor, 2.5% were treated with sodium glucose cotransporter-2 inhibitor, and 3.2% were treated with glucagon-like peptide-1 receptor analogue. With respect to treatment of hypertension and dyslipidemia, 1.3% of enrolled patients were treated with angiotensin-converting enzyme (ACE) inhibitor, 34.2% were treated with angiotensin II receptor blocker (ARB), 1.3% were treated with β-blocker, and 33.5% were treated with statin.Table 1Demographic and clinical characteristics of patient cohort (*N* = 158)Patient characteristicsAge (years)63 (54--69)Sex, male/female (%)91 (57.6)/67 (42.4)Body mass index (kg/m^2^)25.0 (22.1--28.4)Duration of diabetes (years)8 (2--14)SBP (mmHg)130 (120--144)DBP (mmHg)78 (70--87)Fasting plasma glucose (mg/dl)160 (126--217)HbA1c (%)9.5 (8.4--11.5)Fasting insulin (μU/ml)4.7 (3.2--7.6)Total cholesterol (mg/dl)191 (167--219)HDL-C (mg/dl)46 (38--56)TG (mg/dl)134 (102--200)Uric acid (mg/dl)5.2 (4.2--6.3)Bilirubin (mg/dl)0.8 (0.6--0.9)Creatinine (mg/dl)0.68 (0.58--0.83)Creatinine clearance (ml/min)94.6 (75.8--119.7)Urinary albumin (mg/day)12.6 (6.8--44.4)Echocardiography IVS (mm)9 (8--10) PW (mm)9 (8--10) LVMI (g/m^2.7^)80 (71--92) RWT0.39 (0.36--0.41) LVEF (%)67 (64--71)Diabetes treatment Sulfonylurea (%)67 (42.4) Glinide (%)3 (1.9) Biguanide (%)45 (28.5) Thiazolidinedione (%)16 (10.1) α-glucosidase inhibitor (%)26 (16.5) DPP-4 inhibitor (%)82 (51.9) SGLT2 inhibitor (%)4 (2.5) GLP-1 receptor analogue (%)5 (3.2)Other treatment ACE inhibitor (%)2 (1.3) ARB (%)54 (34.2) β-blocker (%)2 (1.3) Statin (%)53 (33.5)Categorical variables are presented as number (%) or median (lower quartile--upper quartile)*DBP* diastolic blood pressure, *HbA1c* hemoglobin A1c, *HDL-C* high-density lipoprotein cholesterol, *IVS* interventricular septum thickness, *LVEF* left ventricular ejection fraction LVMI, left ventricular mass index, *PW* posterior wall thickness, *RWT* relative wall thickness, *SBP* systolic blood pressure, *TG* triglyceride, *DPP-4* dipeptidyl peptidase-4, *SGLT2* sodium glucose cotransporter 2, *GLP-1* glucagon-like peptide-1, *ACE* angiotensin-converting enzyme, *ARB* angiotensin II receptor blocker

The relationships between serum bilirubin concentration and other variables are shown in Table [2](#Tab2){ref-type="table"}. HDL-C and creatinine clearance were positively associated with serum bilirubin concentration. TG, PW, and RWT were inversely associated with serum bilirubin concentration. There was no association between LVMI and serum bilirubin concentration. Additionally, medication statuses of diabetes, hypertension, and dyslipidemia did not affect left ventricular geometry (Supplemental Table 1). Next, we analyzed the relationships between RWT and other variables. Univariate analyses showed that RWT was significantly correlated with DBP (*P* = 0.003), HbA1c (*P* = 0.024), total cholesterol (*P* = 0.043), urinary albumin (*P* = 0.023), and serum bilirubin concentration (*P* = 0.009) (Table [3](#Tab3){ref-type="table"}). A multivariate linear regression analysis that included the factors significant on univariate analysis was performed to identify parameters independently associated with RWT (Table [4](#Tab4){ref-type="table"}). This analysis showed that log RWT was positively correlated with DBP (*P* = 0.010) and that log RWT was inversely correlated with log bilirubin (*P* = 0.003). The median bilirubin concentration was 0.8 mg/dl, so we divided the patients into two groups and analyzed the association of left ventricular geometry with bilirubin concentration. The patients with lower bilirubin had a relatively high risk of concentric remodeling compared with the patients having higher bilirubin at a prevalence of 16.4% vs. 3.5% (*P* = 0.007). The prevalence of normal geometry, eccentric hypertrophy, and concentric hypertrophy were comparable between the lower vs. higher bilirubin groups (32.9%, 35.6%, and 15.1% vs. 45.9%, 41.2%, and 9.4%, *P* = 0.106, *P* = 0.515, and *P* = 0.331 respectively) (Fig. [1](#Fig1){ref-type="fig"}). These findings suggest that low bilirubin concentration may be a risk factor for the progression of concentric remodeling in patients with T2DM.Table 2Correlation between serum bilirubin level and other variablesVariables*ρP* valueAge− 0.0740.354Sex, female0.492Body mass index− 0.0010.996Duration of diabetes− 0.1150.149SBP− 0.1260.115DBP− 0.0360.649Fasting plasma glucose0.0880.269HbA1c− 0.0660.410Fasting insulin− 0.0960.228Total cholesterol− 0.0530.513HDL-C0.2490.002TG− 0.1820.022Uric acid− 0.0830.301Creatinine− 0.0640.425Creatinine clearance0.2530.001Urinary albumin− 0.1440.070Echocardiography IVS (mm)− 0.1530.055 PW (mm)− 0.2260.004 LVMI (g/m^2.7^)− 0.1310.102 RWT− 0.2070.009 LVEF (%)− 0.1040.193*P* values were calculated using Spearman's rank correlation test or the Mann--Whitney *U* test, as appropriate*DBP* diastolic blood pressure, *HbA1c* hemoglobin A1c, *HDL-C* high-density lipoprotein cholesterol, *IVS* interventricular septum thickness, *LVEF* left ventricular ejection fraction LVMI, left ventricular mass index, *PW* posterior wall thickness, *RWT* relative wall thickness, *SBP* systolic blood pressure, *TG* triglyceride Table 3Univariate analysis of factors associated with RWTVariables*ρP* valueAge0.0070.933Sex0.646Body mass index0.0630.435Duration of diabetes0.0230.778SBP0.0330.678DBP0.2350.003Fasting plasma glucose0.0940.241HbA1c0.1800.024Fasting insulin0.0690.390Total cholesterol0.1610.043HDL-C− 0.0440.580TG0.0960.231Uric acid− 0.0530.506Creatinine− 0.0400.615Creatinine clearance− 0.0850.286Urinary albumin0.1810.023Bilirubin− 0.2070.009*P* values were calculated using Spearman's rank correlation test or the Mann--Whitney *U* test, as appropriate*DBP* diastolic blood pressure, *HbA1c* hemoglobin A1c, *HDL-C* high-density lipoprotein cholesterol, *RWT* relative wall thickness, *SBP* systolic blood pressure, *TG* triglyceride Table 4Multivariate linear regression analysis of factors associated with log RWTVariables*ρP* valueDBP0.200.010Log HbA1c0.080.272Log total cholesterol0.040.552Log urinary albumin0.070.409Log bilirubin− 0.230.003*DBP* diastolic blood pressure, *HbA1c* hemoglobin A1c, *RWT* relative wall thickness Fig. 1Left ventricular geometry patterns in lower vs. higher bilirubin groups

Discussion {#Sec7}
==========

Diabetes mellitus is associated with concentric left ventricular remodeling \[[@CR11]\], which is an adverse prognostic marker for cardiovascular events \[[@CR12]\] and is linked to contractile dysfunction \[[@CR13]\]. In the present study, we showed that RWT significantly and inversely correlated with serum bilirubin concentration and that the patients with low bilirubin concentrations had a high prevalence of concentric remodeling. Bilirubin is an end-product of heme catabolism and has long been used in clinical practice as a marker for hepatobiliary and hematopoietic diseases. Furthermore, bilirubin has been recognized for many years as an endogenous antioxidant \[[@CR14]\]. Oxidative stress is an important pathogenic factor in the development of diabetic vascular complications, including cardiomyopathy \[[@CR15]--[@CR17]\]. In addition, suppressing oxidative stress in vivo was reported to prevent diabetic cardiomyopathy \[[@CR18], [@CR19]\]. Previously, we showed a significantly lower prevalence of cardiovascular disease in diabetic patients with Gilbert's syndrome, a congenital hyperbilirubinemia, along with reduced markers of oxidative stress and inflammation \[[@CR20]\]. Strong evidence supports an association between cardiac remodeling and oxidative stress resulting from increased reactive species production and decreased antioxidant defense \[[@CR21]\]. Taken together, bilirubin may have a protective role in the progression of concentric remodeling via suppressing oxidative stress in the patients with T2DM.

The clinical and experimental evidence suggests that the renin--angiotensin--aldosterone system and sympathetic nervous system also play an important role in the process of cardiac remodeling \[[@CR21]\]. In addition, ACE inhibitors, β-blockers, and ARBs have been consistently shown to decrease remodeling in animal model \[[@CR22]--[@CR25]\]. These findings have been validated in clinical trials, and these drugs are currently indicated for patients with an ejection fraction of less than 40% \[[@CR21], [@CR25]\]. However, these medication statuses did not affect left ventricular geometry in the present study. The reason may be that the patients with overt cardiovascular disease were excluded and that few patients took ACE inhibitors or β-blockers in this study. Additionally, a previous study showed that serum bilirubin concentrations were inversely correlated with LVMI in the patients with hypertension who had not received any treatment \[[@CR26]\]. In that study, hypertensive patients with diabetes mellitus were excluded. Compared with their study, the blood pressure of patients enrolled in our study was controlled by antihypertensive medications. For these reasons, there may be no association between LVMI and serum bilirubin concentrations in our study. Additional studies are required to evaluate these correlations in detail.

One limitation of our study was its cross-sectional design. Therefore, a cause-and-effect relationship could not be determined. Another limitation was the uncertainty of the diagnosis of ischemic heart disease. Ischemic heart disease was excluded on the basis only on the absence of symptoms, the lack of previous cardiovascular disease, and electrocardiogram results, indications that may not completely rule out ischemic heart disease. Additionally, the number of participants was relatively small. Further study with a large cohort is necessary for showing stronger correlation.

Conclusion {#Sec8}
==========

This study showed for the first time that serum bilirubin concentrations were inversely correlated with RWT and that the patients with low bilirubin concentrations had a higher prevalence of concentric left ventricular remodeling. Low bilirubin concentrations may be a risk factor for the progression of concentric remodeling in patients with T2DM.
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